Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 7/20 | 0.54 |
| ▸ | MTOR | P42345 | 3/20 | 0.34 |
| ▸ | JAK2 | O60674 | 5/20 | 0.34 |
| ▸ | JAK1 | P23458 | 5/20 | 0.34 |
| ▸ | TYK2 | P29597 | 5/20 | 0.34 |
| ▸ | JAK3 | P52333 | 5/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.31 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.31 |
| ▸ | FASN | P49327 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22922544 | 1.00 | MAP4K1 (0.54) | MAP4K1MTORJAK2JAK1TYK2 | |
| SCHEMBL22922560 | 1.00 | MAP4K1 (0.54) | MAP4K1MTORJAK2JAK1TYK2 | |
| SCHEMBL29868936 | 1.00 | MAP4K1 (0.54) | MAP4K1MTORJAK2JAK1TYK2 | |
| SCHEMBL29869239 | 0.94 | MAP4K1 (0.61) | MAP4K1JAK2JAK1TYK2JAK3 | |
| SCHEMBL22922395 | 0.94 | MAP4K1 (0.61) | MAP4K1JAK2JAK1TYK2JAK3 | |
| SCHEMBL29869467 | 0.94 | MAP4K1 (0.61) | MAP4K1JAK2JAK1TYK2JAK3 | |
| SCHEMBL22922396 | 0.94 | MAP4K1 (0.61) | MAP4K1JAK2JAK1TYK2JAK3 | |
| SCHEMBL22922390 | 0.88 | MAP4K1 (0.67) | MAP4K1JAK2JAK1TYK2JAK3 | |
| SCHEMBL22922389 | 0.88 | MAP4K1 (0.67) | MAP4K1JAK2JAK1TYK2JAK3 | |
| SCHEMBL29869139 | 0.88 | MAP4K1 (0.67) | MAP4K1JAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459958-B2 | Tricyclic compounds as HPK1 inhibitor and the use thereof | BEONE MEDICINES I GMBH (CH) | 2025-11-04 | — | — | US | disclosed |
| US-20220267354-A1 | TRICYCLIC COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF | BEONE MEDICINES I GMBH (CH) | 2022-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220267354-A1 | TRICYCLIC COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF | ULK1, SBK1, PHKG1 | MAP4K1 96/4885MTOR 180/4885JAK2 2099/4885 |
| US-12459958-B2 | Tricyclic compounds as HPK1 inhibitor and the use thereof | ULK1, SBK1, PHKG1 | MAP4K1 96/4885MTOR 180/4885JAK2 2099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.